Investors & partners
“Measure a subject against themselves” is a measurement primitive, not a clinical feature. That is the whole thesis: the same substrate is load-bearing in a regulated clinical market and in six non-regulated ones, and the layering that makes that possible is difficult to copy after the fact.
Intuitive Pathos is an early-stage company with products in development. Nothing is cleared, approved or generally available. The clinical system is investigational. We have not published clinical performance data. Filings are in preparation; zero applications are currently pending.
This page describes a thesis and an architecture, not traction. Nothing on this website is an offer to sell or a solicitation of an offer to buy any security.
Presentation
An interactive 14-slide presentation deck covering the per-subject baseline thesis, architectural moat, seven-market expansion model, and seed stage positioning.
Thesis
Essentially every physiological monitoring product in market answers the same question: is this measurement unusual relative to a population? That question is cheap to ask, has been asked for a century, and is answered adequately by incumbents with far more distribution than we will ever have.
It is also the wrong question for an individual subject, and the people it is most wrong for are the ones least represented in the reference cohort. Replacing the comparison set with the subject themselves changes what the instrument is capable of detecting, and it changes it in a direction clinical medicine has already begun to move — the documented retreat from race-corrected reference ranges and algorithms being the clearest example (see the evidence).
The commercial consequence is that the same core is defensible in markets that share no customer, no channel and no regulator.
Defensibility
None of these is a feature. Each is a structural property that a competitor would have to rebuild from the foundation to match.
01
The substrate is separated from the regulated product, so non-clinical products can ship without inheriting a clinical codebase’s regulatory surface or release cadence. A competitor that built the clinical product first — the natural order — has to perform this extraction later, against a validated device, under change control. That is expensive in a way that compounds.
02
The Wu primitives are implemented once and wrapped everywhere. It is common for a platform at this stage to accumulate several divergent copies of its core numerics without noticing. Consolidating later means reconciling implementations that have quietly disagreed for years.
03
The claims we make about fairness and data movement are enforced by the type system, which makes them auditable rather than assertable. In a market moving toward algorithmic accountability, “we can show you the interface that makes this impossible” is a categorically different position from “we have a policy.”
04
Because the substrate carries no device claim, non-clinical products can reach market, generate real-world data and fund the company on a timeline that is not gated by the clinical pathway — while the clinical pathway proceeds on its own clock.
Markets
The markets below share nothing except the primitive. That is the point — it means no single regulatory, reimbursement or channel outcome determines the company.
| Product | Market | Buyer | Regulatory gate |
|---|---|---|---|
| Pathos Vigil | Acute & critical care | Health system | Device pathway |
| Intuitive‑Me | Consumer wellness | Individual | None — general wellness |
| Pathos Vet | Veterinary care | Practice / hospital | Outside human-device regulation |
| Pathos Guardian | Defense & public safety | Government / agency | Procurement, not clearance |
| Pathos Home | Aging in place | Family / provider | None — general wellness |
| Pathos Workplace | Occupational safety | Employer | None — non-clinical |
| Pathos Wildlife | Conservation research | Institution / NGO | Research use |
Sequencing, resourcing and prioritization across this family are commercial decisions we are happy to discuss directly; we do not publish them.
Founder
Intuitive Pathos was founded by Matthew Lashomb, a registered neuroscience nurse. The framework is a direct generalization of a failure he watched repeatedly in acute care: measurement instruments answering a population question about an individual patient, and the harm landing predictably on the same people.
That origin shows up in the architecture. The constraints are the ones you write when you have personally seen what happens when a safety property is a policy that someone can override on a bad night shift.
A protection you can turn off under pressure was never a protection. It was a preference.
Risks
An investor seed deck that lists no risks is telling you something. Here are the ones we would raise ourselves.
Next step
For diligence materials, technical deep-dives on the layering or the mathematics, or a direct conversation with the founder.
This page is provided for information only. It is not an offer to sell or a solicitation of an offer to buy any security, and it contains forward-looking statements that involve risk and uncertainty.
Regulatory notice. Products described on this site are in development. Pathos Vigil is investigational and has not been cleared or approved by the U.S. Food and Drug Administration or any other regulatory authority, and is not available for sale or clinical use. Non-clinical products, including Intuitive‑Me, are general-wellness offerings and make no diagnostic or therapeutic claim.
Not medical advice. Nothing on this website is medical advice, a diagnosis, or a treatment recommendation. If you have a health concern, contact a qualified clinician. In an emergency, call your local emergency number.